Login to Your Account



AACR Roundup


Thursday, April 7, 2011
• Teva Pharmaceutical Industries Ltd., of Jerusalem, Israel, and OncoGenex Pharmaceuticals Inc., of Bothell, Wash., presented preclinical data on their investigational compound custirsen (OGX-011/TV-1011), which is being investigated in Phase III studies in castrate-resistant prostate cancer. Custirsen is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer types and in response to many cancer treatments. The companies also presented data showing an inhibitory effect of custirsen on heat-shock protein 90 (HSP90) in prostate cancer cells. Inhibition of HSP90 is being investigated as a strategy to treat prostate cancer, and the addition of custirsen may enhance the activity of HSP90 inhibitors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription